Amgen Inc. (formerly Applied Molecular Genetics Inc.) is a multinational biopharmaceutical company. The Company's largest selling product lines are Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Company Growth (employees)
Type
Public
HQ
Thousand Oaks, US
Founded
1980
Size (employees)
19,200 (est)
Website
amgen.com
Amgen was founded in 1980 and is headquartered in Thousand Oaks, US

Key People/Management at Amgen

Robert Bradway

Robert Bradway

Chairman and Chief Executive Officer
Suzanne Blaug

Suzanne Blaug

SVP, Global Marketing and Commercial Development

Amgen Office Locations

Amgen has offices in Thousand Oaks, San Francisco, South San Francisco, Bucharest and in 58 other locations
Thousand Oaks, US (HQ)
One Amgen Center Drive
Show all (62)

Amgen Financials and Metrics

Amgen Financials

Amgen's revenue was reported to be $23 b in FY, 2016 which is a 6% increase from the previous period.
USD

Revenue (FY, 2016)

23 b

Revenue growth (FY, 2015 - FY, 2016), %

6%

Gross profit (FY, 2016)

18.8 b

Gross profit margin (FY, 2016), %

82%

Net income (FY, 2016)

7.7 b

EBIT (FY, 2016)

9.8 b

Market capitalization (16-Oct-2017)

134.2 b

Cash (31-Dec-2016)

3.2 b

EV

165.6 b
Amgen's current market capitalization is $134.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.7 b20.1 b21.7 b23 b

Revenue growth, %

7%8%6%

Cost of goods sold

3.3 b4.4 b4.2 b4.2 b

Gross profit

15.3 b15.6 b17.4 b18.8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.7 b4.1 b3.2 b

Accounts Receivable

2.7 b2.5 b3 b3.2 b

Inventories

3 b2.6 b2.4 b2.7 b

Current Assets

27.4 b34.7 b38.5 b46 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

5.1 b5.2 b6.9 b7.7 b

Accounts Receivable

(38 m)136 m(420 m)(214 m)

Inventories

(7 m)327 m481 m(80 m)

Accounts Payable

(184 m)405 m(12 m)(44 m)
USDY, 2016

EV/EBIT

16.9 x

EV/CFO

16 x

Revenue/Employee

1.2 m

Debt/Equity

1.2 x

Debt/Assets

0.4 x

Financial Leverage

2.6 x
Show all financial metrics

Amgen Market Value History

Amgen Median Salaries

Source: 437 public H-1B filings from Amgen

Traffic Overview of Amgen

Amgen Online and Social Media Presence

Amgen News and Updates

FiercePharmaAsia—China’s new drug policy guidelines, Mylan-Biocon’s Neulasta biosim, C-Bridge hire

China’s national authorities released wide-ranging guidelines for drug policy change, the FDA rejected Mylan and Biocon’s biosimilar of Amgen’s Neulasta due to a manufacturing issue, and China’s investment shop C-Bridge has tapped ex-GlaxoSmithKline executive Hussain as a senior partner.

Amgen targets China in cancer biosimilar development deal with Simcere

Even as it battles against knockoffs of its own biologic drugs, Amgen is steadily growing its own biosimilar portfolio of copies of some of the bestselling cancer and inflammation drugs. Now, with a co-development deal with Simcere, Amgen is taking that effort to China, a country relying heavily on …

No need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backup

Amgen has rolled out a new economic analysis of Repatha’s outcomes study, Fourier, which initially failed to wow the market when unveiled earlier this year. The gist? The PCSK9 drug is cost-effective at $9,669 per year or less, almost $5,000 off its list price.

Roche's hold on Avastin, Herceptin sales loosens as FDA panel backs Amgen and Mylan biosims

Roche took a blockbuster double hit Thursday as the FDA’s Oncologic Drugs Advisory Committee recommended an Amgen biosimilar to Avastin in the morning, and then a Mylan biosim to Herceptin in the afternoon.

Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo

Back in March, Amgen’s Kyprolis posted new data showing it could top Takeda’s Velcade at extending survival. And now, the multiple myeloma-fighter has put up more survival results that will strengthen its case against its rivals.

$AMGN To Breakout Of Bull Flag And Head To This Target Within Days

This article is published in collaboration with Scutify, where you can find real-time markets a
Show more

Amgen Company Life and Culture

You may also be interested in